









Markets
/
Stocks
/
nasdaq-antx
/

AN2 Therapeutics Inc

ANTX

1.141USD

+0.001+0.05%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

31.23MMarket Cap

LossP/E TTM



AN2 Therapeutics Inc

1.141

+0.001+0.05%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of AN2 Therapeutics Inc

Currency: USD Updated: 2025-10-27

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

AN2 Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

278 / 501

Overall Ranking

502 / 4682

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 2 analysts

Buy

Current Rating

1.500

Target Price

+31.58%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

AN2 Therapeutics Inc Highlights

StrengthsRisks

AN2 Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing treatments for rare, chronic, and serious infectious diseases with high unmet needs. Its initial candidate is epetraborole, which is a potential once-daily, oral treatment with a novel mechanism of action for patients with non-tuberculous mycobacterial (NTM) lung disease, a rare, chronic, and progressive infectious disease caused by bacteria known as mycobacteria, which leads to irreversible lung damage and can be fatal. Epetraborole is designed to produce broad-spectrum antimycobacterial activity through inhibition of an essential and universal step in bacterial protein synthesis. Epetraborole is an investigational, boron-containing, orally bioavailable, small molecule inhibitor of bacterial leucyl-tRNA synthetase (LeuRS), an enzyme that catalyzes the attachment of leucine to transfer RNA (tRNA), molecules, an essential step in protein synthesis.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 0.00.

Fairly Valued

The company’s latest PE is -1.08, at a medium 3-year percentile range.

Institutional Selling

The latest institutional holdings are 10.80M shares, decreasing 58.99% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 398.85K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.72.

Financial Health

Currency: USD Updated: 2025-10-27

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.92.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

AN2 Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-10-27

The company’s current valuation score is 8.67, which is higher than the Biotechnology & Medical Research industry's average of 6.98. Its current P/E ratio is -1.08, which is -58.57% below the recent high of -0.45 and -624.78% above the recent low of -7.85.

Score

Industry at a Glance

Previous score

8.67

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 278/501

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-27

The company’s current earnings forecast score is 7.00, which is lower than the Biotechnology & Medical Research industry's average of 8.04. The average price target for AN2 Therapeutics Inc is 1.50, with a high of 2.00 and a low of 1.00.

Score

Industry at a Glance

Previous score

7.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 2 analysts

Buy

Current Rating

1.500

Target Price

+31.58%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

AN2 Therapeutics Inc

ANTX

CRISPR Therapeutics AG

CRSP

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

Ionis Pharmaceuticals Inc

IONS

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-27

The company’s current price momentum score is 3.90, which is lower than the Biotechnology & Medical Research industry's average of 6.80. Sideways: Currently, the stock price is trading between the resistance level at 1.44 and the support level at 1.19, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.81

Change

0.09

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(4)

Neutral(1)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-0.022

Sell

RSI(14)

40.501

Neutral

STOCH(KDJ)(9,3,3)

15.558

Sell

ATR(14)

0.077

Low Volatility

CCI(14)

-104.199

Sell

Williams %R

88.468

Oversold

TRIX(12,20)

-0.149

Sell

StochRSI(14)

0.831

Oversold

Moving Average

Sell(6)

Neutral(0)

Buy(0)

Indicators

Value

Direction

MA5

1.180

Sell

MA10

1.218

Sell

MA20

1.219

Sell

MA50

1.238

Sell

MA100

1.162

Sell

MA200

1.195

Sell

Institutional Confidence

Currency: USD Updated: 2025-10-27

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.11. The latest institutional shareholding proportion is 39.53%, representing a quarter-over-quarter decrease of 34.22%. The largest institutional shareholder is The Vanguard, holding a total of 1.04M shares, representing 3.79% of shares outstanding, with 9.34% increase in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Coastlands Capital LP

2.82M

Adjuvant Global Health Technology Fund LP

2.00M

-15.91%

Almitas Capital LLC

1.43M

+8.77%

Easom (Eric)

1.30M

+0.78%

Readnour (Robin Shane)

1.24M

+36.86%

The Vanguard Group, Inc.

Star Investors

1.04M

Brii Biosciences Ltd,.

927.20K

Pfizer Inc

715.29K

Peapod Lane Capital LLC

582.77K

+0.33%

Zakrzewski (Joseph S)

551.42K

+1.95%

Risk Assessment

Currency: USD Updated: 2025-10-27

There is no risk assessment score for the company; the Biotechnology & Medical Research industry's average is 3.49. The company's beta value is -0.03. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.